Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects

Combined Therapy of Low-Dose Angiotensin Receptor–Neprilysin Inhibitor and Sodium–Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects

Although cancer-therapy-related cardiac dysfunction (CTRCD) is a critical issue in clinical practice, there is a glaring lack of evidence regarding cardiotoxicity management. To determine an effective and suitable dosage of treatment using angiotensin receptor–neprilysin inhibitors (ARNI) with sodiu...

Full description

Bibliographic Details
Main Authors: Donghyun Kim, Gyuho Jang, Jaetaek Hwang, Xiaofan Wei, Hyunsoo Kim, Jinbae Son, Sang-Jae Rhee, Kyeong-Ho Yun, Seok-Kyu Oh, Chang-Myung Oh, Raekil Park
Format: Article
Language:English
Published: MDPI AG 2022-11-01
Series:Pharmaceutics
Subjects:
angiotensin receptor–neprilysin inhibitor
sodium–glucose cotransporter 2 inhibitor
heart failure
doxorubicin
peroxisome proliferator-activated receptors
Online Access:https://www.mdpi.com/1999-4923/14/12/2629

Internet

https://www.mdpi.com/1999-4923/14/12/2629

Similar Items